Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial
Open accessAbstract
OBJECTIVE: To determine whether the immunogenicity of a single dose infant priming schedule of serogroup C meningococcal (MenC) conjugate vaccine is non-inferior to a two dose priming schedule when followed by a booster dose at age 12 months. DESIGN: Phase IV open label randomised controlled trial carried out from July 2010 until August 2013 SETTING: Four centres in the United Kingdom and one centre in Malta. PARTICIPANTS: Healthy infants aged 6-12 weeks followed up until age 24 months. INTERVENTIONS: In the priming phase of the trial 509 infants were randomised in a 10:10:7:4 ratio into four groups to receive either a single MenC-cross reacting material 197 (CRM) dose at 3 months; two doses of MenC-CRM at 3 and 4 months; a single MenC-polysaccharide-tetanus toxoid (TT) dose at 3 months; or no MenC doses, respectively. Haemophilus influenzae type b (Hib)-MenC-TT vaccine was administered to all infants at 12 months of age. All infants also received the nationally routinely recommended vaccines. Blood samples were taken at age 5, 12, 13, and 24 months. MAIN OUTCOME MEASURE: MenC serum bactericidal antibody assay with rabbit complement (rSBA) one month after the Hib-MenC-TT vaccine. Non-inferiority was met if the lower 95% confidence limit of the difference in the mean log10 MenC rSBA between the single dose MenC-CRM and the two dose MenC-CRM groups was >-0.35. RESULTS: The primary objective was met: after a Hib-MenC-TT booster dose at 12 months of age the MenC rSBA geometric mean titres induced in infants primed with a single MenC-CRM dose were not inferior to those induced in participants primed with two MenC-CRM doses in infancy (660 (95% confidence interval 498 to 876) v 295 (220 to 398)) with a corresponding difference in the mean log10 MenC rSBA of 0.35 (0.17 to 0.53) that showed superiority of the single over the two dose schedule). Exploration of differences between the priming schedules showed that one month after Hib-MenC-TT vaccination, MenC rSBA ≥ 1:8 was observed in >96% of participants previously primed with any of the MenC vaccine schedules in infancy and in 83% of those who were not vaccinated against MenC in infancy. The MenC rSBA geometric mean titres induced by the Hib-MenC-TT boost were significantly higher in children who were primed with one rather than two MenC-CRM doses in infancy. Only priming with MenC-TT, however, induced robust MenC bactericidal antibody after the Hib-MenC-TT booster that persisted until 24 months of age. CONCLUSIONS: MenC vaccination programmes with two MenC infant priming doses could be reduced to a single priming dose without reducing post-boost antibody titres. When followed by a Hib-MenC-TT booster dose, infant priming with a single MenC-TT vaccine dose induces a more robust antibody response than one or two infant doses of MenC-CRM. Bactericidal antibody induced by a single Hib-MenC-TT conjugate vaccine dose at 12 months of age (that is, a toddler only schedule), without infant priming, is not well sustained at 24 months. Because of rapid waning of MenC antibody, programmes using toddler only schedules will still need to rely on herd protection to protect infants and young children.Trial registration Eudract No: 2009-016579-31; NCT01129518; study ID: 2008_06 (http://clinicaltrials.gov).
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
After immunization with 2 doses of the capsular group C meningococcal vaccine in infancy, only 41% of infants still had protective levels of antibody by the time of the booster dose, administered 7 months later.
“after immunization with 2 doses of the capsular group C meningococcal vaccine in infancy, only 41% of infants still had protective levels of antibody by the time of the booster dose, administered 7 months later75.”
From A guide to vaccinology: from basic principles to new developments (2021) · cites this paper as [75]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction
Trotter, C. L., Andrews, N. J., Kaczmarski, E. B., Miller, E., & Ramsay, M. E. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16725-1 · Cited by 571 · see citing works
Maslanka, S., Gheesling, L. L., Libutti, D. E., Donaldson, K. B. J., Harakeh, H. S., Dykes, J. K., Arhin, F. F., Devi, S. J., Frasch, C. E., Huang, J., et al. (1997) · Clinical and Diagnostic Laboratory Immunology · doi:10.1128/cdli.4.2.156-167.1997 · Cited by 427 · see citing works
Andrews, N. J., Borrow, R., & Miller, E. J. (2003) · Clinical and Vaccine Immunology · doi:10.1128/cdli.10.5.780-786.2003 · Cited by 323 · see citing works
Self-citationBorrow, R., Andrews, N. J., Goldblatt, D., & Miller, E. (2001) · Infection and Immunity · doi:10.1128/iai.69.3.1568-1573.2001 · Cited by 317 · see citing works
Self-citationMeningococcal Serogroup C Conjugate Vaccine Is Immunogenic in Infancy and Primes for Memory
Richmond, P., Borrow, R., Miller, E. J., et al. (1999) · The Journal of Infectious Diseases · doi:10.1086/314753 · Cited by 241 · see citing works
Self-citationMaslanka, S. E., Gheesling, L. L., Libutti, D. E., et al. (1997) · Cited by 214 · see citing works
Leach, A., Twumasi, P., Kumah, S., et al. (1997) · The Journal of Infectious Diseases · doi:10.1093/infdis/175.1.200 · Cited by 209 · see citing works
Meningococcal C conjugate vaccine: the experience in England and Wales
Campbell, H., Borrow, R., Salisbury, D., & Miller, E. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.04.067 · Cited by 168 · see citing works
Self-citationFairley, C. K., Begg, N. T., Borrow, R., et al. (1996) · The Journal of Infectious Diseases · doi:10.1093/infdis/174.6.1360 · Cited by 151 · see citing works
Self-citationBorrow, R., Andrews, N. J., Findlow, H., Waight, P., Southern, J., Crowley-Luke, A., Stapley, L., England, A., Findlow, J., & Miller, E. (2009) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00384-09 · Cited by 115 · see citing works
Self-citationBorrow, R., Goldblatt, D., Andrews, N. J., Southern, J., Ashton, L., Deane, S., Morris, R., Cartwright, K. A. V., & Miller, E. (2002) · The Journal of Infectious Diseases · doi:10.1086/344324 · Cited by 114 · see citing works
Self-citationBorrow, R., Goldblatt, D., Finn, A. H. R., Southern, J., Ashton, L., Andrews, N. J., Lal, G., Riley, C., Rahim, R., Cartwright, K. A. V., et al. (2003) · Infection and Immunity · doi:10.1128/iai.71.10.5549-5555.2003 · Cited by 103 · see citing works
Self-citationReconsideration of the Use of Meningococcal Polysaccharide Vaccine
Granoff, D. M., & Pollard, A. J. (2007) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3180cc2c25 · Cited by 89 · see citing works
Self-citationEffectiveness of meningococcal serogroup C vaccine programmes
Borrow, R., Abad, R., Trotter, C., van der Klis, F. R. M., & Vazquez, J. A. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.07.083 · Cited by 88 · see citing works
Self-citationGlobal practices of meningococcal vaccine use and impact on invasive disease
Ali, A., Jafri, R. Z., Messonnier, N. E., Tévi‐Bénissan, C., Dürrheim, D. N., Eskola, J., Fermon, F., Klugman, K. P., Ramsay, M. E., Sow, S. O., et al. (2014) · Pathogens and Global Health · doi:10.1179/2047773214y.0000000126 · Cited by 72 · see citing works
Southern, J., Borrow, R., Andrews, N. J., Morris, R., Waight, P., Hudson, M., Balmer, P., Findlow, H., Findlow, J., & Miller, E. (2008) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00420-08 · Cited by 68 · see citing works
Self-citationSouthern, J., Crowley-Luke, A., Borrow, R., Andrews, N. J., & Miller, E. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.07.060 · Cited by 56 · see citing works
Self-citationEffectiveness of Serogroup C Meningococcal Conjugate Vaccine
Wals, P. D., Deceuninck, G., Lefebvre, B., Boulianne, N., & Serres, G. D. (2011) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31820e8638 · Cited by 52 · see citing works
Kaaijk, P., ENDE, A. V. D., Berbers, G. A. M., et al. (2012) · BMC Infectious Diseases · doi:10.1186/1471-2334-12-35 · Cited by 42 · see citing works
Findlow, H., Borrow, R., Andrews, N. J., Waight, P., Sheasby, E., Matheson, M., England, A., Goldblatt, D., Ashton, L., Findlow, J., et al. (2012) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31824f34e6 · Cited by 31 · see citing works
Self-citationKhatami, A., Snape, M. D., John, T. M., Westcar, S., Klinger, C. L., Rollinson, L., Boutriau, D., Mesaros, N. E., Wysocki, J., Gałaj, A., et al. (2010) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181f728fd · Cited by 29 · see citing works
Self-citationGroup B meningococcal vaccine: recommendations for UK use
Pollard, A. J., Riordan, A., & Ramsay, M. E. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60226-9 · Cited by 27 · see citing works
Self-citationStoof, S. P., van der Klis, F. R. M., van Rooijen, D. M., Knol, M. J., Sanders, E. A. M., & Berbers, G. A. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100651 · Cited by 23 · see citing works
Updated Recommendations on the Use of Meningococcal Vaccines
Brady, M. T., Byington, C. L., Davies, H. D., et al. (2014) · PEDIATRICS · doi:10.1542/peds.2014-1383 · Cited by 20 · see citing works
Díez‐Domingo, J., Planelles, M. V., Baldó, J. M., Úbeda-Sansano, I., Jubert, A., Puig‐Barberà, J., & Gutiérrez-Gimeno, M. V. (2010) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181d9e653 · Cited by 20 · see citing works
Pollard, A. J., Green, C., Sadarangani, M., & Snape, M. D. (2013) · Archives of Disease in Childhood · doi:10.1136/archdischild-2012-303103 · Cited by 20 · see citing works
Self-citationMODERN TRENDS IN MORTALITY FROM MENINGOCOCCAL DISEASE IN AUSTRALIA
Simpkins, D., Wood, N., Jelfs, J., et al. (2009) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181accde8 · Cited by 17 · see citing works
Schuermann, L., Martínez, S., Weddington, G., et al. (2014) · Perspectives on Global Issues in Communication Sciences and Related Disorders · doi:10.1044/gics4.2.75 · Cited by 16 · see citing works
Khatami, A., Clutterbuck, E., Thompson, A., McKenna, J. A., Pace, D., Birks, J., Snape, M. D., & Pollard, A. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101672 · Cited by 11 · see citing works
Self-citationHeavens, M. A. C. (1968) · BMJ · doi:10.1136/bmj.4.5625.253-b · Cited by 1 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
Cited by
Sorted by citations
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616 · see citing works
Self-citationA guide to vaccinology: from basic principles to new developments
Pollard, A. J., & Bijker, E. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00479-7 · Cited by 1,593 · see citing works
Self-citation
- Authors
- Pace, D., Khatami, A., McKenna, J., Campbell, D., Attard-Montalto, S., Birks, J., Voysey, M., White, C., Finn, A., Macloed, E., Faust, S. N., Kent, A. L., Heath, P. T., Borrow, R., Snape, M. D., & Pollard, A. J.
- Affiliations
- Mater Dei Hospital (MT)
- University of Oxford (GB)
- University Hospitals Bristol NHS Foundation Trust (GB)
- University Hospital Southampton NHS Foundation Trust (GB)
- St George's, University of London (GB)
- Manchester Royal Infirmary (GB)
- Corresponding author
- Pace, D.
- ORCID
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2015-04-01
- Volume
- 350
- Issue
- apr01 16
- Pages
- h1554-h1554
- ISSN
- 1756-1833 (ISSN-L)
- PMC
- PMC4382115
- OpenAlex
- W2065339964
- Cited by
- 28
- References
- 30
- Citations by year
- 2026: 1 · 2025: 1 · 2023: 2 · 2021: 5 · 2020: 5 · 2019: 1 · 2018: 3 · 2017: 2 · 2016: 6 · 2015: 2
- FWCI
- 3.61
- Type
- journal article
- Language
- en
- Update notices
- correction (2016-05-06)
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- BMJ (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- St George's Online Research Archive (St George's University of London) (acceptedVersion)
- OAR@UM (University of Malta) (acceptedVersion, other-oa)
- ePrints Soton (University of Southampton) (acceptedVersion)
- Explore Bristol Research (submittedVersion)
- Funders
- Wellcome Trust
- Topics
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Life Sciences › Immunology and Microbiology › Microbiology › Microbial infections and disease research
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Keywords
- booster vaccination, immunogenicity, bactericidal antibodies, Haemophilus influenzae type b, infants, non-inferiority, vaccination schedule, serotype 1
- MeSH terms
- Child, Preschool, Female, Follow-Up Studies, United Kingdom, Humans, Immunization Schedule, Immunization, Secondary, Infant, Male, Malta, Models, Statistical, Vaccines, Conjugate, Meningococcal Vaccines, Serum Bactericidal Antibody Assay
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
